In separate actions, two pharmaceutical makers have acquired the rights to a novel testosterone agent and a patented formulation for interstitial cystitis/painful bladder syndrome (IC/PBS).
Endo International plc announced acquisition rights to testosterone nasal gel (Natesto) from Trimel BioPharma SRL. The drug was approved by the FDA in May 2014.
Endo said it expects the transaction to close in early 2015.
No comments:
Post a Comment